Biostatistical consulting supported a study evaluating prostate cancer screening methods and outcomes. Clinical data analysis assessed screening effectiveness, early detection rates, and patient outcomes to inform evidence-based screening recommendations.
The decision behind the question
A study team needed to evaluate how well screening approaches performed on early detection and downstream patient outcomes, not just on test accuracy.
Data and methods used
Clinical data was analyzed to estimate detection rates, false positive burden, and outcome differences between screening strategies, with time-to-event methods used for the outcome comparison.
What the analysis found
- •Detection rate improvements did not translate proportionally into outcome improvements.
- •False positive burden differed enough between strategies to change the overall balance.
- •Benefit concentrated in a definable risk group rather than being spread across the screened population.
What changed as a result
Screening recommendations were framed around the risk group where benefit was demonstrable, with the false positive burden stated explicitly.
Related work is grouped under Healthcare, and the methods used here are described in more detail under analytical capabilities.
Other Averisys Analytics studies related to Prostate Cancer Screening
Each study documents the question, the data, the method, and what the finding made possible. Select any title to read the full write-up.
Trusted by leading organizations
Averisys Analytics guarantees its security.
